Observational studyMuscle & nerve2026
Fat-Fraction Quantification Using Three-Point Dixon Technique in Duchenne Muscular Dystrophy and Its Correlation With Clinical Progression and Genotypic Characteristics: A Single Centre One-Year Prospective Study.
Observational study in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
INTRODUCTION/
aimsMuscle fat fraction (MFF) quantification using the Dixon magnetic resonance imaging (MRI) technique is an emerging objective, non-invasive biomarker in Duchenne muscular dystrophy (DMD). This study aimed to evaluate the relationship between MFF and disease progression, specifically its correlation with functional decline and genotypic characteristics.
methodsIn this single-center prospective observational study, genetically confirmed, independently ambulant boys with DMD underwent MFF quantification of pelvic and thigh muscles. Functional measures including Medical Research Council (MRC) sum score, North Star Ambulatory Assessment (NSAA), and six-minute walk test (6MWT) were assessed at baseline, 6, and 12 months.
resultsForty boys (median age 8 years) were included. Highest mean MFF was observed in gluteal muscles (51.74% ± 23.26 right; 50.29% ± 24.07 left), while hamstrings showed the lowest. MFF demonstrated strong inverse correlations with all functional measures across most muscle groups at all time points. Baseline quadriceps MFF showed the strongest correlation with rate of decline of 6MWT over 1 year (r = 0.668 (CI 0.450, 0.811) and r = 0.564 (CI 0.307, 0.745) for right and left respectively). Adductor MFF was significantly higher in proximal versus distal variants (p = 0.049 and p = 0.037). DISCUSSION: Baseline MFF, particularly in quadriceps, predicts functional decline in ambulatory DMD. Genotype-specific adductor involvement suggests novel, variant-specific spatial differences in muscle involvement. Longitudinal studies integrating genotype-phenotype analyses could validate MFF as a biomarker for clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.